Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
Neorich Biopharma Tech Co (OTCPK:PHBID) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Neorich Biopharma Tech Co EPS (Diluted) Related Terms
Neorich Biopharma Tech Co EPS (Diluted) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PHBID vs DVLP, CSTF, BLMS: EPS (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neorich Biopharma Tech Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neorich Biopharma Tech Co PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neorich Biopharma Tech Co's PE Ratio distribution charts can be found below:
* The bar in red indicates where Neorich Biopharma Tech Co's PE Ratio falls into.
Neorich Biopharma Tech Co EPS (Diluted) Calculation
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Neorich Biopharma Tech Co's Diluted EPS for the fiscal year that ended in Sep. 2022 is calculated as
EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neorich Biopharma Tech Co (PHBID) has a EPS (Diluted) of $0.00 as of Jun. 2023. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Neorich Biopharma Tech Co and its competitors.
Is Neorich Biopharma Tech Co's EPS (Diluted) too high?
Neorich Biopharma Tech Co's current EPS (Diluted) is $0.00.
How does Neorich Biopharma Tech Co's EPS (Diluted) compare to DVLP and CSTF?
Neorich Biopharma Tech Co's EPS (Diluted) of $0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Drug Manufacturers company?
A good EPS (Diluted) depends on the Drug Manufacturers industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on Neorich Biopharma Tech Co and its competitors. Neorich Biopharma Tech Co's current EPS (Diluted) is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neorich Biopharma Tech Co stock overvalued right now?
Neorich Biopharma Tech Co (PHBID) has a current EPS (Diluted) of $0.00. The current EPS (Diluted) is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For Neorich Biopharma Tech Co (PHBID), the current EPS (Diluted) is $0.00 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PHBID has been successfully added to your 
